The global organ transplant immunosuppressant drugs market exhibits a highly consolidated vendor landscape. The top five companies held more than 90% of the market in 2014. These companies boast a strong and diverse product portfolio that has helped them attain a leading position in the market. Transparency Market Research (TMR) finds that in order to gain a stronger footprint, the leading companies are continuously engaged in the research and development of novel therapeutics.
“Despite the impending patient expiry of blockbuster drugs, the leading companies are looking to update their pipelines to ensure sustainable growth in the market,” said a lead TMR analyst. Besides this, the companies are also focusing on collaborations and mergers and acquisitions to strengthen their value chain.
Rising Organ Replacement Therapies Boosts Sales of Immunosuppressant Drugs
The increasing incidence of life-threatening diseases has augmented the demand for organ replacements and transplants as last resorts of treatment in case of organ failure or disabilities. Due to this, the number of people registering for organ transplantation has significantly increased as well. The increase in geriatric population directly influences the demand for organ transplants since aged people are more vulnerable to kidney and heart diseases. The rising incidence of chronic ailments will therefore fuel demand for organ transplant immunosuppressant drugs.
High Cost of Organ Replacement Surgeries Poses Threat to Market
“Despite witnessing increasing demand, the high cost of organ transplant procedures limits the scope for the market’s expansion,” observed the TMR analyst. Non-adherence of patients to immunosuppressive medicines across developing regions is often related to their high cost and the patient’s inability to pay for the same. Furthermore, the high cost of post-transplantation care presents a significant barrier to the development of transplantation capacity in middle-income countries. The inadequate insurance coverage also limits the sales of organ transplant immunosuppressant drugs in these countries.
The development of immunosuppressant drugs help overcome conditions related to organ rejection. Significant advances have been made in the field of medicine and technology, yet a large section of global population is yet become aware about organ transplantation and donation. This has created a considerable shortage of donor organs, thus negatively impacting the sales of immunosuppressant drugs.
Besides this, the advent of stem cell therapies could eventually reduce the need for organ transplants. This also threatens the growth prospects of the organ transplant immunosuppressant drugs market.
Nevertheless, extensive studies are underway to develop and test novel immunosuppressant therapeutics to prevent organ rejection. Such research and development activities will create opportunities for the market to gain from in the forthcoming years.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967
According to TMR, the global organ transplant immunosuppressant drugs market stood at US$5.1 bn in 2014. Rising at a CAGR of -5.0%, the market is expected to reach US$3.2 bn by the end of 2023.
Based on the type of transplantation performed across the world each year, the demand for immunosuppressant drugs used in kidney transplantation was the highest in 2014. The segment held over 53.4% of the market’s revenue in the year. Regionally, North America dominated the global market with a share of 46.2% in 2014. The region is expected to continue to be a key contributor to the market through the report’s forecast period from 2015 to 2023.
This review is based on findings published by TMR, in a report, titled “Organ Transplant Immunosuppressant Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
Inadequate insurance coverage to limit sales of immunosuppressant drugs in developing countries.
North America dominated the global immunosuppressant drugs market in 2014 with a share of 46.2%.
Advent of stem cell therapy will contribute to declining CAGR of the market at -5.0% from 2014 to 2023.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453